David L. Lacey - 04 May 2023 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for David L. Lacey
Issuer symbol
NRIX
Transactions as of
04 May 2023
Net transactions value
$0
Form type
4
Filing time
04 May 2023, 19:57:16 UTC
Previous filing
16 Jun 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 04 May 2023 Common Stock 25,000 $9.44 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 4, 2024, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

Exhibit 24 - Power of Attorney